Trump Tells American Pharma, Serve the Country, Not Globalists

In a series of initiatives over the last week, President Trump took executive action to push American pharmaceutical companies to stop serving Wall St. and London and start serving the interests of the American people. The actions continue the trend to heed the wake-up call of the Covid-19 pandemic and reverse the decades-long decline of American manufacturing at the hands of the mythical fools’ gold of “globalization”.

On Tuesday, July 28, Trump announced a deal brokered with Kodak Corporation to begin producing pharmaceutical precursors in an underutilized, repurposed factory in Rochester, N.Y. The deal involves a $765 million loan under the Defense Production Act, to again produce in the U.S. the vital chemicals needed for all medicines. Such production had long ago been outsourced by globalist corporations, creating a national security vulnerability that became all too apparent with the onset of the coronavirus pandemic.

The day before, Trump traveled to North Carolina’s Research Triangle and announced a series of measures to speed up government and private sector collaboration to “rapidly develop a vaccine for COVID-19, and ensure accelerated manufacturing and distribution once ready.” The initiative, taken as part of “Operation Warp Speed, involves ramping up production of vaccine products at two advanced manufacturing sites in North Carolina and Texas.

All this followed just days after Trump signed four executive orders designed to force big Pharma companies to lower their drug prices to U.S. consumers. Trump had long advocated reigning in prescription drug prices but was stymied by free-trade Republicans and bloviating Democrats, who, though talking about lower drug prices, have always deferred to their Wall St. backers, and blocked all efforts.

Despite working cooperatively, and profitably, with Trump on vaccine and therapeutic development for Covid-19, Big Pharma howled at Trump’s orders, launching an ad campaign attacking them. Pfizer CEO Alex Bourla told a conference call with investors, “We have plans to invest in both R&D and manufacturing in the United States. If finalized, these new executive orders could force us to rethink those plans, consider job reductions and add to the economic and health anxiety already widely felt in our country.” Trump shot back in several tweets blasting Big Pharma’s ad campaign.

These developments typify the fight that’s necessary to rebuild U.S. manufacturing. Globalists will howl, but Trump has good reason to believe the voters will respond well to him, if his actions are not completely censored by Silicon Valley’s inquisitors.

GET MORE UPDATES FROM LAROUCHEPAC
WE’RE FIGHTING TO DEFEND THE PRESIDENCY